Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 76–77
HOS-139944 · Präparat HOS-098408
76 Concomitant Effect on concentration† Recommendations concerning co- medicinal product mean ratio (90% confidence administration with letermovir interval) for AUC, Cmax (likely mechanism of action) Antivirals acyclovir‡ ↔ acyclovir No dose adjustment required. (400 mg single AUC 1.02 (0.87, 1.2) dose)/ letermovir Cmax 0.82 (0.71, 0.93) (480 mg daily) valacyclovir Interaction not studied. No dose adjustment required. Expected: ↔ valacyclovir Herbal products St. John’s wort Interaction not studied. St. John’s wort may decrease plasma (Hypericum Expected: concentrations of letermovir. perforatum) ↓ letermovir Co-administration of letermovir and St. John’s wort is contraindicated. (P-gp/UGT induction) HIV medicinal products efavirenz Interaction not studied. Efavirenz may decrease plasma Expected: concentrations of letermovir. ↓ letermovir Co-administration of letermovir and (P-gp/UGT induction) efavirenz is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valacyclovir (HOS-139811) efavirenz (HOS-087947) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage bac83f7e198e58cee9aef8d163d01669631b97caf31cddd1a11e0d287341c717 · Zeichen 16486–17940 im Abschnitt